華潤醫療(01515.HK)擬收購江蘇省一間營利性醫院
格隆匯 3 月 28日丨華潤醫療(01515.HK)發佈公吿，2021年3月28日，江華管理(公司的全資附屬公司)與售股股東、賣方及Sinophi Hospitals訂立股份購買協議。根據股份購買協議，江華管理有條件同意收購而賣方有條件同意出售銷售股份(亦即Sinophi Hospitals的控股股權)，代價為人民幣8.83億元。於本公吿日期，Sinophi Hospitals間接持有淮陰醫院80%股權，淮陰醫院為一間位於江蘇省淮安市的營利性綜合醫院，其開放牀位數約為1,190牀。
公吿表示，收購事項有助於集團獲取稀缺的醫療業務資源，並將作為集團開啟長三角區域醫療業務拓展布局的起點。淮陰醫院位於長三角地區江蘇省淮安市，是淮安市淮陰區唯一一所具備等級的醫院，作為該區的龍頭醫院擁有佔該區內近39%的住院服務市場份額，其在醫療技術水準、醫院品牌口碑、政府認可程度等方面都積累了較好的基礎。淮陰醫院作為區內轉診的唯一入口，也是獲取區內基層診療流量的核心渠道，具備區內其他醫療機構難以複製的競爭優勢。淮陰醫院已於兩年前完成營利性改制，其產權歸屬清晰、經營狀況良好、管理規範有序，是近年來市場中較為稀缺的優質醫療業務資源。集團在長三角地區暫無具規模的醫療機構佈局，而收購事項將為集團在長三角地區獲取一所擁有逾1,000個開放牀位、年門急診量逾45萬人次的二級甲等營利性綜合醫院，實為集團落子長三角區域的關鍵舉措，並將成為集團未來在長三角進一步擴大醫療服務業務佈局的起點。
另外，集團亦擬於淮陰醫院打造“大專科小綜合”的業務模式。考慮到淮陰醫院當前外科基礎良好，特別是其骨科已基具備三級醫院技術水準，集團將藉助醫院二期工程新增住院空間的契機，聚焦打造以關節和脊柱外科為骨科特色的專業科室，精益求精以形成該醫院突出的專科特色。同時，集團亦將引入旗下三九腦科醫院的醫療資源，在神經內科方面針對性提升淮陰醫院腦血管病的綜合診治水準，並在神經外科方面重點提升神經外科急症的綜合診治水準、加快培育具競爭力的針對特定病種能力，為淮陰醫院提供新的增長點與專科競爭力，與區域內的公立醫院形成差異化發展，打造“大專科小綜合”發展模式，並藉此進一步整合區內醫療服務資源，擴大市場份額，鞏固區域領先的競爭地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
